Major update on high cholesterol: ‘Game-changing’ medicine might save up to 30,000 lives.
CHOLESTEROL CAN CAUSE A RANGE OF SERIOUS HEALTH PROBLEMS, but despite the fact that the illness can be life-threatening, there are few ways to adequately control it. A new medicine, on the other hand, has the potential to dramatically improve outcomes for people with high cholesterol levels.
More than two out of every five people in England are thought to have excessive cholesterol, putting them at risk for a variety of life-threatening heart problems. When identified at high levels in those under the age of 45, “bad cholesterol” can considerably raise their risk of a heart attack or stroke by the age of 75. Currently, doctors prescribe cholesterol-lowering statins to middle-aged people who have higher-than-average LDL levels. A new ‘game-changing’ medicine, on the other hand, might save up to 30,000 lives in the following decade.
The NHS is getting ready to roll out the treatment for those who have had a heart attack or stroke and have high cholesterol.
Inclisiran is an experimental medication that is given twice a year by injection to remove bad cholesterol from the blood.
According to Novartis, the small interfering RNA (siRNA) would be given as a subcutaneous injection to patients with hypercholesterolemia or mixed dyslipidaemia to lower LDL cholesterol levels.
The medicine is expected to prevent 55,000 heart attacks and strokes, as well as save tens of thousands of individuals from dying prematurely.
How to live longer: Five ways to turn back the clock on your biological age by three years in just a few weeks
While there is no evidence on the drug’s cardiovascular results, the National Institute for Health and Care Excellence (NICE) says it is cost-effective in those who have previously suffered cardiovascular problems.
The health inspector also said that the medicine was effective in treating those who had failed to respond to earlier therapies.
“Inclisiran is a potential game-changer in sparing thousands of patients from dying prematurely from heart attacks and strokes,” said NICE deputy chief executive and director of the Centre for Health Technology Evaluation.
“As a result, we’re delighted to be able to suggest it as a cost-effective NHS choice, backed by the ground-breaking agreement between NHS England, NHS Improvement, and Novartis.
“Over the following three years, the medicine might be given to up to 300,000 people with high cholesterol or mixed dyslipidaemia who have already had a cardiovascular incident.
“Brinkwire Summary News,” said NHS chief executive Amanda Pritchard.